redoxpareina

Redoxpareina is a synthetic redox-active compound first reported in 2018 by a research group at the Institute for Molecular Medicine. It belongs to the class of quinone‑derived antioxidants and features a pyrrolo[3,2‑b]pyridine core fused to a para‑aminobenzoquinone moiety. The structural arrangement gives redoxpareina a reversible two‑electron transfer potential, allowing it to scavenge reactive oxygen species while cycling between oxidized and reduced forms. The compound is typically synthesized via a copper‑mediated coupling of 2‑aminopyridine derivatives and para‑nitrobenzoquinone under acidic conditions.

In vitro studies demonstrate that redoxpareina effectively quenches hydroxyl radicals, superoxide anions, and lipid peroxyl radicals at concentrations as low as 10 µM. Its antioxidant efficacy has been compared favorably to that of vitamin E and N‑acetylcysteine in cell culture models of oxidative stress. In addition to antioxidant activity, research suggests redoxpareina modulates the Nrf2 signalling pathway, up‑regulating endogenous detoxifying enzymes such as glutathione peroxidase and superoxide dismutase.

Potential applications of redoxpareina span food technology, where it is used as a natural preservative to inhibit oxidation of edible oils, to pharmaceutical development, where its cytoprotective properties are explored in neurodegenerative disease models. Despite promising results, limited data exist on its pharmacokinetics and long‑term safety in humans, and further research is required to evaluate its clinical utility. Current literature also highlights research into redoxpareina analogues with enhanced water solubility and tissue penetration, aiming to improve its therapeutic profile.